Search Results

You are looking at 211 - 220 of 441 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy

-free survival, there was clear benefit for nivolumab as adjuvant therapy (22.4 vs 11.0 months; HR, 0.69; P =.0003), with the benefit sustained over time. Nivolumab was favored in all subgroups. “This is the most robust data we have seen showing any benefit

Full access

Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook

tumor specimens of patients enrolled in randomized studies of adjuvant 5-fluorouracil with levamisole or leucovorin compared with no adjuvant therapy. 98 This study showed no improvement in overall survival in patients with stage II and III colon cancer

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

toxicity calculator, then they may opt for surgical resection and discussion of the role of adjuvant therapy based on the pathologic risk identified at the time of surgery. Table 2. Criteria for Cisplatin Ineligibility For patients who do not receive NAC

Full access

Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins

and the decreasing likelihood of receiving neoadjuvant/adjuvant therapy. 42 , 43 , 47 A reason for these findings has been the increasing prevalence of comorbid disease in older age groups. Consistent with the literature, 10 , 38 , 42 , 43 , 47 – 52

Full access

Andrew H. Ko and Christopher H. Crane

relative importance of chemotherapy and radiation as adjuvant therapy ( Table 1 ). The ESPAC-1 trial, 2 conducted by the European Study Group for Pancreatic Cancer, used a 2-by-2 factorial design in which patients were randomly assigned after surgery to 1

Full access

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

individually been evaluated in the neoadjuvant and adjuvant settings with mixed results. 74 – 77 At this time, the guidelines of the AASLD and the European Association for the Study of the Liver do not recommend neoadjuvant or adjuvant therapy in most patients

Full access

Gayathri Nagaraj and Cynthia X. Ma

. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Robert L. Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, Mark A. Morgan, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole R. McMillian, and Miranda Hughes

with cervical cancer either as 1) definitive therapy for those with locally advanced disease or for those who are poor surgical candidates, or 2) adjuvant therapy after radical hysterectomy for those who have one or more pathologic risk factors (eg

Full access

Thomas Olencki

.” Furthermore, “vismodegib may be considered for neoadjuvant therapy, but there is no role for it as adjuvant therapy at this time,” concluded Dr. Olencki. New Agents Are Needed for MCC Considered to be one of the most lethal skin cancers, MCC is an

Full access

Toni K. Choueiri

, they should not be given outside of a clinical trial, Dr. Choueiri noted. Numerous biomarkers are under investigation, but none should be clinically applied at this time, he said. Adjuvant Therapy and Other Histologies In contrast to metastatic